SCHEMBL4475209

SCHEMBL4475209

CN(Cc1ccc(NC(=O)c2[nH]c3ccc(OCc4ccccc4)cc3c2OC(=O)C(F)(F)F)cc1)C1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
DHODH Q02127 2/20 0.40
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
LTA4H P09960 1/20 0.39
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPKAPK2 P49137 1/20 0.38
RAB9A P51151 1/20 0.38
S1PR1 P21453 6/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4473787 0.89 SMN1; SMN2 (0.45) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL4482193 0.87 MAPT (0.43) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL4461647 0.86 SMN1; SMN2 (0.43) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL4474709 0.84 SMN1; SMN2 (0.51) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL4466681 0.83 SMN1; SMN2 (0.49) KDM4EMAPTALDH1A1SMN1; SMN2TDP1
SCHEMBL4465734 0.82 GSK3B (0.49) KDM4EMAPTALDH1A1SMN1; SMN2TDP1
Trifluoroacetic Acid SCHEMBL4475204 0.81 KDM4E (0.48) KDM4EALDH1A1DHODHHPGDHSD17B10
SCHEMBL4482778 0.79 MAPT (0.43) KDM4EMAPTALDH1A1GAASMN1; SMN2
SCHEMBL13864710 0.78 KDM4E (0.53) KDM4EMAPTALDH1A1SMN1; SMN2DHODH
SCHEMBL4470196 0.76 ALDH1A1 (0.40) KDM4EMAPTALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7531668-B2 2-arylcarboxamide-nitrogenous heterocycle compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-05-12 US disclosed
US-20070299070-A1 2-Arylcarboxamide-Nitrogenous Heterocycle Compound MSD K.K. (JP) 2007-12-27 US disclosed
EP-1798221-A1 2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299070-A1 2-Arylcarboxamide-Nitrogenous Heterocycle Compound MCHR2, MCHR1, NPY2R KDM4E 2454/4885MAPT 4323/4885ALDH1A1 1060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.